Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Judge: Lilly should settle Zyprexa case
A federal judge is urging Eli Lilly to negotiate a worldwide settlement with Zyprexa plaintiffs, who are asking for some $7.7 billion. As you know, Lilly has already agreed paid $1 billion to settle claims about the antipsychotic drug's side effects. The company is under state and federal investigation for its Zyprexa marketing. Now, the drugmaker faces claims that it marketed Zyprexa improperly and overcharged for it, too. Insurers and labor unions claim that Lilly hid the drug's risks, spread misinformation about its effectiveness, and promoted it off-label, and are suing the company under the Racketeer Influenced and Corrupt Organizations act (RICO).
In a draft order issued last week, U.S. District Judge Jack Weinstein said the case against Lilly is strong enough to justify a trial and noted that the company may have pushed questionable uses for the antipsychotic drug. "There is sufficient evidence of fraud under RICO to go to a jury," the judge concluded. "A global settlement...is desirable."
- read the story in the Indianapolis Star
Related Articles:
Lilly, Alaska settle Zyprexa suit for $15M
Lilly gears up for Alaska's Zyprexa trial
Did Lilly chief support off-label promos?
Former FDAer: Lilly hid risks for profit
Lilly strengthens Zyprexa warnings
Comments
Zyprexa has generated a lot of bad press for Eli Lilly and they still have unresolved Zyprexa settlement claims.
Eli Lilly is 'reaping the whirlwind' for aggressive marketing of Zyprexa that has caused suffering and deaths.
Abilify is now the most popular anti-psychotic favored among psychiatrist. What the managers at Eli Lilly should consider is how Zyprexa is being avoided by doctors they aren't prescribing it for new patients at all anymore.
--
Daniel Haszard 4 year Zyprexa patient who got diabetes from it.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


